In conclusion, our platform for discriminating the tumour profiles of three IRs, LAG-3, TIM-3, and TIGIT, may have an impact on predicting both outcome and the immune microenvironment in RCC. The gene discussed is HAVCR2; the disease is renal cell carcinoma.